Breaks Categories: News

MondayDec 28, 2020 11:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ Investigational New Drug (“IND”) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (“GBM”). The IND is now approved and in effect as filed with the U.S. Food and Drug…

Continue Reading

MondayDec 28, 2020 10:08 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market under Nasdaq rules at a price of $3.85 per share. “We believe that the closing of this transaction with a single, health care-dedicated institutional investor is further evidence that the potential of our gene therapies for cancer and diabetes is gaining recognition within the community…

Continue Reading

WednesdayDec 23, 2020 10:36 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share, and 2,000,000 shares of its Series D convertible preferred stock at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen. Acuta Capital, New Enterprise Associates (“NEA”), OrbiMed and Venrock Healthcare Capital Partners, among others, participated in…

Continue Reading

WednesdayDec 23, 2020 10:20 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor. The agreement outlines the purchase and sale of 3,116,884 shares of Genprex common stock; the purchase price of those shares will be $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules. The agreement, which is expected to close on or before Dec. 24, 2020, also stipulates that no warrants will be issued in connection with the transaction. The offering closing is subject to the…

Continue Reading

WednesdayDec 23, 2020 9:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the update, the shares of common stock and warrants are being sold together at a combined public offering price of $2.00 per share and warrant. The warrants will have an exercise price of $2.20 per share and will be immediately exercisable and expire five years from…

Continue Reading

TuesdayDec 22, 2020 1:21 pm

BioMedNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

TPT Global Tech (OTC: TPTW), a provider of telecommunications, medical technology, media content for domestic and international syndication as well as technology solutions, today announced the release of two new products and services for use at its TPT Med Tech division. These include its "QuikLAB" App, designed for use in monitoring patient testing and vaccination history, and its "QuikPASS" Mobile App. QuikPASS is designed to allow entrance to any facility or country based on patient test and vaccination results on a real-time basis worldwide. The QuikPASS App will be offered free of charge to U.S. and international consumer markets. TPT…

Continue Reading

TuesdayDec 22, 2020 12:28 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer. The company recently announced the successful manufacturing technology transfer to commercial contract development and manufacturing organizations (“CDMOs”) as well as the successful engineering run of REQORSA, which passed all testing specifications. “The scaled-up production of clinical-grade REQORSA is yet another significant manufacturing milestone…

Continue Reading

TuesdayDec 22, 2020 11:13 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) CEO Talks Benefits of Disposable Brain Diagnostic Tools

Brain Scientific (OTCQB: BRSF) co-founder and CEO Boris Goldstein penned a recent article for “Healthcare” magazine. Titled “Brain Scientific: Neurology’s need for disposable solutions,” the article provides an overview of the need for new devices in the neurology market and the advantages of disposable brain diagnostic tools. Goldstein noted that his interest in brain diagnostic tools began when he was studying at college, where he used clustering analysis for Rorschach testing. As the founder of BrainRX, he was involved in pre-Alzheimer diagnostic and software development, and he was always searching for places to obtain data for artificial analysis or data correlation.…

Continue Reading

TuesdayDec 22, 2020 10:30 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Finalizes Agreement to Provide RPM Solution to Presbyterian Medical Services

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has inked an agreement with one of the largest integrated healthcare systems in the state of New Mexico to provide remote patient monitoring (“RPM”). The partnership with Presbyterian Medical Services begins Jan. 1, 2021. The agreement, which followed a rigorous request for proposal (“RFP”) process, reflects DRIO’s shift in focus to B2B2C and outlines the company’s commitment to provide access to Dario's next-generation, AI-powered digital therapeutics tools and quality care to patients living with chronic conditions, such as diabetes and hypertension. "We are very pleased to partner with Presbyterian Medical Services in…

Continue Reading

FridayDec 18, 2020 1:33 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Marks Significant Milestone with Commencement of CSE Trading

Tryp Therapeutics (CSE: TRYP) today announced that its common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "TRYP" effective Dec. 18, 2020. "Trading on the CSE is a significant milestone in Tryp's mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicines," said Tryp CEO James Kuo, MD. "All of the drugs within our portfolio have well characterized safety profiles including our drug candidate for soft tissue sarcoma, which has been in multiple phase 2 clinical trials. We are looking forward to utilizing the experience and dedication of our management team…

Continue Reading